

Optimal control of HIV resistance and tuberculosis co-infection using treatment intervention

Fatmawati and Hengki Tasman

<https://doi.org/10.12980/apjtd.7.2017D6-400>

Asian Pac J Trop Dis 2017; 7(6): 366-373



also developed by scimago:



SCIMAGO INSTITUTIONS RANKINGS



Scimago Journal & Country Rank

Enter Journal Title, ISSN or Publisher Name



- Home
- Journal Rankings
- Country Rankings
- Viz Tools
- Help
- About Us



Asian Pacific Journal of Tropical Disease


Country	Netherlands - SJR Ranking of Netherlands
Subject Area and Category	Medicine Infectious Diseases Microbiology (medical)
Publisher	Elsevier BV
Publication type	Journals
ISSN	22221808
Coverage	2011-ongoing

[Join the conversation about this journal](#)

25

H Index





Asian Pacific Journal of Tropical Disease

← Show this widget in your own website

Q3 Microbiology (medical) best quartile

SJR 2018 0.25

powered by scimagojr.com

Just copy the code below and paste within your html code:

```
<a href="https://www.scimagojr.com/journalsearch.php?q=21100197903&tip=s...">
```


Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2019. Data Source: Scopus®

EST MODUS IN REBUS
Horatio (Satire 1, 1, 106)

Asian Pacific Journal of Tropical Disease

APJTD

Monthly

Aims & Scope

Asian Pacific Journal of Tropical Disease (APJTD) is administrated by Editorial Office of Asian Pacific Journal of Tropical Disease, which aims to establish an international academic communicating platform for researchers of tropical medicine and public health workers, especially those of the Asian Pacific region and worldwide specialists and scholars on tropical disease research to prevent and control the prevalence of global tropical disease.

APJTD is an international academic journal and is distributed worldwide. The journal first reports the latest prevalent disease in the world, such as avian influenza (H5N1, H5N2, H5N8, and H7N9), Ebola virus disease and MERS; pharmaceutical research of resistance to epidemiology, such as research of artemisinin against malaria; meanwhile, Chagas disease (American trypanosomiasis), dengue, helminths, African trypanosomiasis, leishmaniasis, leprosy (Hansen's disease), lymphatic filariasis, malaria, onchocerciasis (river blindness), schistosomiasis (snail fever), sexually transmitted infections, TB/HIV coinfection, Tuberculosis, hookworm, trichuriasis, treponematoses, Buruli ulcer, human African trypanosomiasis, dracunculiasis, leptospirosis, strongyloidiasis, foodborne trematodiases, Neurocysticercosis, scabies, flavivirus infection, Ebola hemorrhagic fever, Lassa fever, Marburg fever, yellow fever, encephalitis, West Nile virus, Ross River virus, Rocky Mountain spotted fever, cat-scratch disease, Q-fever, typhus,

cryptosporidiosis, cholera, dysentery, enzootic hepatitis, typhoid fever, trichinosis, hydatid, avian influenza, influenza, polio, SARS, kala azar, plague, tsutsugamushi, babesiasis, Lyme disease, African meningitis, red tide, epidemic polyarthritis, amebiasis, giardiasis, tropical ulcer, rabies, Hanta virus, cutaneous larva migrans, myiasis, tungiasis, *etc.* are the main content of the journal. Our research scope includes all aspects of infectious diseases (bacterial, viral, parasitic, fungal, *etc.*), nutritional and deficiency diseases and venom studies.

Original article, review, epidemiological investigation, clinical research, management and decision-making, case report, editorial, short communication, letter to editor related to the aim and scope of APJTD are encouraged.

The journal is aimed at researchers, physicians, clinicians in the field and not in the field, medical scientists, educators, administrators, allied health professionals, medical students and policy makers.

The journal is proud to have an international and diverse editorial board that will assist and facilitate the publication of articles that reflect a global view on tropical disease as well as emphasizing our focus on supporting the needs of public health practitioners.

APJTD will allow us to seek opportunities to work with others who share mutual goals, and to enhance our work through partnership, and to uphold the standards of our profession and contribute to its advancement.

Administrated by

Editorial Office of Asian Pacific Journal of Tropical Disease, *Haikou, China*

Edited by

Editorial Board of Asian Pacific Journal of Tropical Disease
<http://www.apjtc.com/board.html>
<http://www.apjtc.com/zy/f4.pdf>

Published by

Editorial Office of Asian Pacific Journal of Tropical Disease
<http://www.apjtc.com/news/pc.html>
E-mail: apjtd@yahoo.com; apjtd@apjtc.com

Editor-in-Chief

Jeffrey M. Bethony, *Washington DC, USA*
Santiago Mas-Coma, *Valencia, Spain*
Jong-Yil Chai, *Seoul, Korea*
Leonard Ernest Gustavin Mboera, *Dar es Salaam, Tanzania*
<http://www.apjtc.com/>

President

Executive Editor-in-Chief

Shunhai Qu, *Haikou, China*

Printed by

Haikou Yongfa Printing Co., Ltd
<http://www.yf999.com/>

ISSN: 2222-1808

CODEN: APJTD8

Website

<http://www.apjtc.com>
Online submission: apjtd@yahoo.com; apjtd@apjtc.com

Electronic edition

An electronic version is available at
<http://www.sciencedirect.com/science/journal/22221808>

Volume of distribution: 3000 Price (Single issue) \$ 31.5

Copyright © 2017 Editorial Office of Asian Pacific Journal of Tropical Disease. All rights reserved.



Covered by ZR, OAJI, CSA, CA, CABA, Global Health, Scopus, EM, IC, UPD

Statement of Ethical, Conflict of Interest, Human/Animal Rights, Informed Consent, please refer to Information for authors in inside back cover.

Copyright © 2017 by the Asian Pacific Journal of Tropical Disease. All rights reserved.

Contents

Infectious disease research

- Epidemiology of hand foot mouth disease in Northern Thailand in 2016: A prospective cohort study 321

Panupong Upala, Tawatchi Apidechkul, Wipob Suttana, Ratakorn Aimkosa

- Profile of dengue hepatitis in children from India and its correlation with WHO dengue case classification 327

Neelam Mohan, Deepak Goyal, Sakshi Karkra, Vanamail Perumal

Entomological research

- Surveillance of *Aedes* mosquitoes in different residential types in central zone of Shah Alam, Selangor 332

Siti Nur Anis Hasnan, Nazri Che Dom, Zulkiflee Abd Latif, Faiz Madzlan

- Occurrence of high resistance to DDT in the field population of arboviruses vector *Culex pipiens* complex in Iran 341

Reza Zeidabadi Nezhad, Hassan Vatandoost, Mohamad Reza Abai, Navid Dinparast Djadid, Ali Raz, Mohamd Mahdi Sedaghat, et al.

Microbiological research

- Detection of *Mycobacterium marinum* in clinically asymptomatic Siamese fighting fish (*Betta splendens*) from ornamental fish shops in Chiang Mai Province, Thailand 344

Anucha Sirimalaisuwan, Pradthana Teeraruk, Penpisoot Kanjanapitakchai, Thattawan Kaewsakhorn, Panyisa Potibut, Surachai Pikulkaew

- Biofilm formation and antimicrobial resistance in *Klebsiella pneumoniae* isolated from patients visiting a tertiary care center of Nepal 347

Hari Prasad Nepal, Puja Neopane, Rojeet Shrestha, Rajendra Gautam, Rama Paudel, Shamshul Ansari, et al.

- Prevalence and predictors of *Helicobacter pylori* infection among patients attending a healthcare facility in North-Central Nigeria 352

Victor Baba Oti, Grace Rinnecit Pennap, Ochiche Dennis, Abimiku Samuel Ajegena, Moses Peter Adoga

Original article

- Validated HPTLC technique for simultaneous evaluation of biomarkers gallic acid and quercetin in *Trichosanthes dioica* Roxb.: A systematic approach for quality control of herbals 356

Md. Sarfaraj Hussain, Hend Ismail, Sheeba Fareed, Mohammad Ali

Letter to editor

Role of behavioural communication change in integrated vector management against vector borne diseases especially dengue in Punjab, Pakistan 362

Hazrat Bilal, Zia Ullah, Saboor Ahmad, Sumrin Sahar

Mini-review

Bat related virus infection: A summary on reports from Thailand 364

Beuy Joob, Viroj Wiwanitkit

Review


Optimal control of HIV resistance and tuberculosis co-infection using treatment intervention 366

Fatmawati, Hengki Tasman

Campylobacter in the environment: A major threat to public health 374

Hussein Hasan Abulreesh, Sameer Rushdi Organji, Khaled Elbanna, Gamal Ebrahim Haridy Osman, Meshal Helal Kareem Almalki, Iqbal Ahmad

Cover image: The prevalence rate and infestation profile of *Aedes* mosquitoes in central zone of Shah Alam, Selangor. Details can be obtained in page 337.




Statement of Ethical, including Conflict of Interest, Human/Animal Rights, Informed Consent, please refer to Information for authors in inside back cover.

Copyright © 2017 by the Asian Pacific Journal of Tropical Disease. All rights reserved.

[Serial parameters] ISSN 2222-1808 2011 m A4 64 en P \$ 31.5 3000 12 2017-6

Asian Pacific Journal of Tropical Disease

journal homepage: <http://www.apjtc.com>



Review article <https://doi.org/10.12980/apjtd.7.2017D6-400>

©2017 by the Asian Pacific Journal of Tropical Disease. All rights reserved.

Optimal control of HIV resistance and tuberculosis co-infection using treatment intervention

Fatmawati^{1*}, Hengki Tasman²

¹Department of Mathematics, Faculty of Science and Technology, Universitas Airlangga, Surabaya 60115, Indonesia

²Department of Mathematics, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok 16424, Indonesia

ARTICLE INFO

Article history:

Received 2 Nov 2016

Received in revised form 21 Nov, 2nd revised form 5 Dec 2016

Accepted 17 Feb 2017

Available online 8 Jun 2017

Keywords:

Tuberculosis
HIV resistance
Stability
Optimal control

ABSTRACT

In this paper we presented a mathematical model of the spread of HIV and tuberculosis (TB) co-infection considering the resistance of HIV to antiretroviral (ARV) drugs. The model also included anti-TB and ARV treatments as system control variables. For the model without controls, we investigated the existence and stability of equilibria based on three basic reproduction numbers corresponding to the TB and two strains HIV infection. We also performed sensitivity analysis to determine the dominant factor controlling the spread. Then, the optimal control condition was derived using Pontryagin Maximum Principle on the model to achieve the goal of minimizing the number of infected population. The numerical simulations of the optimal control were also performed to illustrate the results.

1. Introduction

HIV infection attacks human immune system. It could develop into AIDS if the infection is not treated properly. A weakened immune system of patients with HIV infection or AIDS will lead to a variety of bacteria/virus infections (opportunistic infections). Until now, there is still no effective cure or vaccine available for HIV infection or AIDS. However, antiretroviral (ARV) drugs could be used for treatment. ARV drugs could control the growth of HIV[1]. Currently, ARV drugs have been used widely in many countries. Without proper use of ARV drugs, HIV strains could be drug-resistant[2]. ARV drug resistance could cause failure of HIV treatment and spread of the infection among population.

Tuberculosis (TB) is usually transmitted through the air

contaminated with *Mycobacterium tuberculosis* that is released when patients with TB cough, talk or sneeze. TB can be prevented and cured with anti-TB drugs. Treatment of TB cases is one of the main strategies for TB control because it can break the chain of transmission. Despite the effective treatments that have been developed, TB remains one of the most destructive bacterial infections in humans. TB infection is a very common opportunistic infection that affects HIV patients. TB is one of the leading causes of death among HIV patients. In 2015, almost 35% of deaths among HIV patients are due to TB[3].

Mathematical models could be used for understanding the dynamic of the spread of HIV and TB co-infection. Many researchers have modeled the dynamics of HIV and TB co-infection[4-6]. For instance, Mallela *et al.*[4] developed a novel mathematical model that evaluates treatment strategies for HIV and TB co-infected individuals. A research[5] proposed a mathematical model to study the dynamic of TB for the spread of HIV in a logistically-growing population. Sharomi *et al.*[6] used a deterministic model to study the synergistic interaction between TB and HIV co-infection, with many of the essential biological and epidemiological characteristics of TB and HIV infection. Mathematical models with optimal

*Corresponding author: Fatmawati, Department of Mathematics, Faculty of Science and Technology, Universitas Airlangga, Surabaya 60115, Indonesia.

Tel: +62 31593 0700

Fax: +62 31593 6502

E-mails: fatmawati@fst.unair.ac.id, fatma47unair@gmail.com

Foundation Project: by the Indonesian Directorate General for Higher Education (DIKTI) through DIPA DITLITABMAS Universitas Airlangga 2015 according to SK Rektor (No.: 516/UN3/2015).

The journal implements double-blind peer review practiced by specially invited international editorial board members.

control considering HIV and TB co-infection also have been established. Recently, Augusto and Adekunle[7] have used optimal control strategies associated with treating symptomatic individuals with TB using the two-strain TB-HIV/AIDS transmission model. A simple model to control the spread of HIV and TB co-infection was proposed[8]. In this paper, the model proposed previously[8] was developed by adding the factor of ARV drug resistance.

In the present paper, we constructed a model of HIV drug resistance and TB co-infection transmission with controls of anti-TB and ARV treatment. Then the model was analyzed, and some numerical simulations were performed to illustrate the effectiveness of the treatments.

2. Model formulation

We assumed that population is homogeneous and closed. We considered two strains of HIV, namely, the sensitive strain of HIV and the resistant strain of HIV which resists to ARV drugs.

The total population, denoted by N, was classified into seven disjoint subpopulations, namely, the susceptible subpopulation (S), the TB-infected subpopulation (I), the sensitive-HIV infected subpopulation (H_s), the resistant-HIV infected subpopulation (H_r), the TB and sensitive-HIV infected subpopulation (H_{st}), the TB and resistant-HIV infected subpopulation (H_{rt}) and the AIDS subpopulation (A).

We assumed that the susceptible subpopulation could not get TB and HIV infections simultaneously. The subpopulations A, H_{st} and H_{rt} were assumed to be isolated, so that they cannot infect anyone. The TB infected subpopulation (I) was assumed to be not susceptible to HIV.

We supposed the anti-TB treatment (u₁) and the ARV treatment (u₂) as the control efforts to reduce TB and HIV infections, respectively. The control functions u₁ and u₂ were defined on closed interval [0, t_f], where 0 ≤ u_i(t) ≤ 1, t ∈ [0, t_f], i = 1, 2 and t_f denotes the end time of the controls.

We used the transmission diagram in Figure 1 for deriving our model.

The model is as follows:

$$\begin{aligned} \frac{dS}{dt} &= \Lambda + u_1\alpha_1 I - \beta_t SI - (\beta_{hs}H_s + \beta_{hr}H_r)S - \delta S \\ \frac{dI}{dt} &= \beta_t SI - u_1\alpha_1 I - (\delta + \mu_t)I \\ \frac{dH_s}{dt} &= \beta_{hs}SH_s - \sigma_s\beta_t H_s I - (\delta + (1-u_2)\gamma_1)H_s + u_1\alpha_s H_{st} \\ \frac{dH_r}{dt} &= \beta_{hr}SH_r - \sigma_r\beta_t H_r I - (\delta + (1-u_2)\gamma_2)H_r + u_1\alpha_r H_{rt} \\ \frac{dH_{st}}{dt} &= \sigma_s\beta_t H_s I - u_1\alpha_s H_{st} - (\delta + \mu_{st} + (1-u_2)\gamma_3)H_{st} \\ \frac{dH_{rt}}{dt} &= \sigma_r\beta_t H_r I - u_1\alpha_r H_{rt} - (\delta + \mu_{rt} + (1-u_2)\gamma_4)H_{rt} \\ \frac{dA}{dt} &= (1-u_2)(\gamma_1 H_s + \gamma_2 H_r + \gamma_3 H_{st} + \gamma_4 H_{rt}) - (\delta + \mu_a)A. \end{aligned}$$

Model (1) has region of biological interest

$$\Omega = \{(S, I, H_s, H_r, H_{st}, H_{rt}, A) \in \mathbb{R}_+^7 : 0 \leq N \leq \frac{\Lambda}{\delta}\},$$

and the vector field of model (1) on the boundary does not point to the exterior, so model (1) is well-posed in the region Ω. All of the parameters used in the model (1) are non-negative and the description of the parameters is given in Table 1.

Table 1

Parameters of model (1).

Description	Parameter	
Recruitment rate	Λ	
Natural death rate	δ	
Infection rate of TB	β _t	
Recovery rate of TB	α _t	
TB-induced death rate	μ _t	
AIDS-induced death rate	μ _a	
	Sensitive strain	Resistant strain
Infection rate for HIV	β _{hs}	β _{hr}
Recovery rate from TB of HIV-TB co-infection	α _s	α _r
Progression rate from HIV infection to HIV-TB co-infection	σ _s	σ _r
Disease HIV-TB induced death rate	μ _{st}	μ _{rt}
Progression rate from HIV infection to AIDS	γ ₁	γ ₂
Progression rate from HIV-TB co-infection to AIDS	γ ₃	γ ₄




Figure 1. A two strain HIV and TB co-infection transmission diagram.

We want to minimize the number of HIV and TB co-infections while keeping the costs of applying anti-TB and ARV treatment controls as low as possible. The cost function is defined as

$$J(u_1, u_2) = \int_0^{t_f} \left(I + H_{st} + H_{rt} + A + \frac{c_1}{2}u_1^2 + \frac{c_2}{2}u_2^2 \right) dt, \tag{2}$$

where, c₁ and c₂ are the weighting constants for anti-TB and ARV treatment efforts, respectively. We take a quadratic form for measuring the control cost[7,9,10]. The terms c₁u₁² and c₂u₂² represent the cost associated with anti-TB and ARV treatment controls respectively. Larger values of c₁ and c₂ will imply higher implementation cost for anti-TB and ARV treatment efforts.

Our aim is to find an optimal control pair u_1^* and u_2^* such that

$$J(u_1^*, u_2^*) = \min_{\Gamma} J(u_1, u_2), \tag{3}$$

where, $\Gamma = \{(u_1, u_2) | 0 \leq u_i \leq 1, i=1,2\}$.

3. Model analysis

Consider model (1) without the control functions u_1 and u_2 . Let

$$R_t = \frac{\Lambda \beta_t}{\delta(\delta + \mu_t)}$$

$$R_s = \frac{\Lambda \beta_{hs}}{\delta(\gamma_1 + \delta)}$$

$$R_r = \frac{\Lambda \beta_{hr}}{\delta(\gamma_2 + \delta)}$$

Parameters R_t , R_s and R_r are basic reproduction ratios corresponding to the TB infection, the sensitive-HIV and resistant-HIV infections, respectively. These ratios represent the number of secondary cases of primary case during the infectious period due to the type of infection [11,12].

By setting $u_1 = u_2 = 0$, model (1) has six equilibria [with respect to coordinate $(S, I, H_s, H_r, H_{st}, H_{rt}, A)$], these are,

1. The disease-free equilibrium $E_0 = (\frac{\Lambda}{\delta}, 0, 0, 0, 0, 0, 0)$
2. The TB endemic equilibrium $E_t = (\frac{\delta + \mu_t}{\beta_t}, \frac{\delta(R_t - 1)}{\beta_t}, 0, 0, 0, 0, 0)$

which exists if $R_t > 1$.

3. The sensitive-HIV endemic equilibrium

$$E_s = (\frac{\delta + \gamma_1}{\beta_{hs}}, 0, \frac{\delta(R_s - 1)}{\beta_{hs}}, 0, 0, 0, \frac{\gamma_1 \delta(R_s - 1)}{\beta_{hs}(\delta + \mu_a)})$$

which exists if $R_s > 1$.

4. The resistant-HIV endemic equilibrium

$$E_r = (\frac{\delta + \gamma_2}{\beta_{hr}}, 0, 0, \frac{\delta(R_r - 1)}{\beta_{hr}}, 0, 0, \frac{\gamma_2 \delta(R_r - 1)}{\beta_{hr}(\delta + \mu_a)})$$

which exists if $R_r > 1$.

5. The sensitive-HIV and TB endemic equilibrium

$$E_{hs} = (\frac{\delta + \mu_t}{\beta_t}, I^s, H_s^s, 0, H_{st}^s, 0, A^s),$$

where

$$I^s = \frac{(\delta + \gamma_1)(R_s - 1)}{\delta \beta_t},$$

$$H_s^s = \frac{\delta}{\beta_{hs}}(R_t - 1) - \frac{(\delta + \gamma_1)(R_s - 1)}{\beta_{hs} \delta},$$

$$H_{st}^s = \frac{\delta \beta_t I^s}{\delta + \mu_{st} + \gamma_3},$$

$$A^s = \frac{\gamma_1 H_s^s + \gamma_3 H_{st}^s}{\delta + \mu_a}.$$

The equilibrium E_{hs} exists if $R_s > R_t > 1$ and $\delta \beta_t R_t (R_t - 1) > (\delta + \gamma_1)(R_s - R_t)$.

6. The resistant-HIV and TB endemic equilibrium

$$E_{hr} = (\frac{\delta + \mu_t}{\beta_t}, I^r, 0, H_r^r, 0, H_{rt}^r, A^r),$$

where

$$I^r = \frac{(\delta + \gamma_2)(R_r - 1)}{\delta \beta_t},$$

$$H_r^r = \frac{\delta}{\beta_{hr}}(R_t - 1) - \frac{(\delta + \gamma_2)(R_r - 1)}{\beta_{hr} \delta},$$

$$H_{rt}^r = \frac{\delta \beta_t I^r}{\delta + \mu_{rt} + \gamma_4},$$

$$A^r = \frac{\gamma_2 H_r^r + \gamma_4 H_{rt}^r}{\delta + \mu_a}.$$

The equilibrium E_{hr} exists if $R_r > R_t > 1$ and $\delta \beta_t R_t (R_t - 1) > (\delta + \gamma_2)(R_r - R_t)$.

The following theorems give the stability criteria of the equilibria.

Theorem 1. The disease-free equilibrium E_0 is locally asymptotically stable if $R_t, R_s, R_r < 1$ and unstable if $R_t, R_s, R_r > 1$.

Proof. Linearizing model (1) near the equilibrium E_0 gives eigenvalues $-\delta, -(\delta + \gamma_3 + \mu_s), -(\delta + \gamma_4 + \mu_r), -(\delta + \mu_a), (\delta + \mu_t)(R_t - 1), (\delta + \gamma_1)(R_s - 1)$ and $(\delta + \gamma_2)(R_r - 1)$. It is clear that all of the eigenvalues are negative if $R_t, R_s, R_r < 1$. So, if $R_t, R_s, R_r < 1$, the equilibrium E_0 is locally asymptotically stable. Otherwise, it is unstable.

Theorem 2. Supposing the TB endemic equilibrium E_t exists. It is locally asymptotically stable if $R_t > 1, R_t > R_s$ and $R_t > R_r$, otherwise it is unstable.

Proof. Linearizing model (1) near the equilibrium E_t gives eigenvalues $-(\delta + \mu_a), -(\delta + \mu_{st} + \gamma_3), -(\delta + \mu_{rt} + \gamma_4), -\delta \beta_t (R_t - 1) - \frac{\Lambda \beta_{hs}}{\delta R_t R_s} (R_t - R_s), -\delta \beta_t (R_t - 1) - \frac{\Lambda \beta_{hr}}{\delta R_t R_r} (R_t - R_r)$, and the roots of quadratic equation $x^2 + \delta R_t x + \delta(\delta + \mu_t)(R_t - 1) = 0$. It is observed that all of the eigenvalues are negative if $R_t > 1, R_t > R_s$ and $R_t > R_r$.

Theorem 3. Supposing the sensitive-HIV endemic equilibrium E_s exists. It is locally asymptotically stable if $R_s > 1, R_s > R_t$ and $R_s > R_r$, otherwise it is unstable.

Proof. Linearizing model (1) near the equilibrium E_s gives eigenvalues $-(\delta + \mu_a), -(\delta + \mu_s + \gamma_3), -(\delta + \mu_r + \gamma_4), -(\delta + \gamma_2) \frac{(R_s - R_r)}{R_s}, -(\delta + \mu_t) \frac{(R_s - R_t)}{R_s}$, and the roots of quadratic equation $x^2 + \delta R_s x + (\delta^2 + \delta \gamma_1)(R_s - 1) = 0$. Clearly, all of the eigenvalues are negative if $R_s > 1, R_s > R_t$ and $R_s > R_r$.

Theorem 4. Supposing the resistant-HIV endemic equilibrium E_r exists. It is locally asymptotically stable if $R_r > 1, R_r > R_s$ and $R_r > R_t$, otherwise it is unstable.

Proof. Linearizing model (1) near the equilibrium E_r gives eigenvalues $-(\delta + \mu_a), -(\delta + \mu_{st} + \gamma_3), -(\delta + \mu_{rt} + \gamma_4), -(\delta + \gamma_1) \frac{(R_r - R_s)}{R_r}, -(\delta + \mu_t) \frac{(R_r - R_t)}{R_r}$ and the roots of quadratic equation $x^2 + \delta R_r x + (\delta^2 + \delta \gamma_2)(R_r - 1) = 0$. It is observed that all of the eigenvalues are negative if $R_r > 1, R_r > R_s$ and $R_r > R_t$.

Next, we investigated the sensitivity of the basic reproduction ratios R_t, R_s and R_r to the parameters in the model. The aim of this analysis is to determine the parameters that have a high impact on the basic reproduction ratios. Using the reported approach [13], we derived the sensitivity indices of R_t, R_s and R_r to each parameters.

The normalized forward sensitivity index of variable which depends differentially on parameter l is defined as

$$\gamma_l^{R_0} := \frac{\partial R_0}{\partial l} \times \frac{l}{R_0} \tag{4}$$

For example, the sensitivity index of R_t with respect to β_t is

$$\gamma_{\beta_t}^{R_t} := \frac{\partial R_t}{\partial \beta_t} \times \frac{\beta_t}{R_t} = 1 \tag{5}$$

By using the parameter values in Table 2, the sensitivity indices of R_t, R_s and R_r with respect to parameters $\Lambda, \delta, \mu_t, \beta_{hs}, \gamma_1, \beta_{hr}$ and γ_2

are listed in Table 3.

Table 2

Parameter values.

Parameter	Value	Reference	Parameter	Value	Reference
Λ	50000/year	[7]	α_r	1/year	Assumed
δ	0.02/year	[7]	μ_t	0.02/year	[6]
β_t	0.00031/year	Assumed	μ_{st}	0.03/year	[6]
β_{hs}	0.00045/year	Assumed	μ_{rt}	0.03/year	Assumed
β_{hr}	0.00035/year	Assumed	μ_α	0.03/year	Assumed
\bar{C}_s	1.2/year	[6]	γ_1	0.01/year	Assumed
\bar{C}_r	1.2/year	[6]	γ_2	0.05/year	Assumed
α_t	1.4/year	Assumed	γ_3	0.08/year	Assumed
α_s	1/year	Assumed	γ_4	0.08/year	Assumed

Table 3

Sensitivity indices to some parameters of model (1).

Parameter (o)	Sensitivity index γ_o^R	Parameter (o)	Sensitivity index γ_o^R	Parameter (o)	Sensitivity index γ_o^R
Λ	1	Λ	1	Λ	1
β_t	1	β_{hs}	1	β_{hr}	1
δ	-1.5	δ	-1.667	δ	-1.286
μ_t	-0.5	γ_1	-0.333	γ_2	-0.714

The interpretation of the sensitivity index $\gamma_{\beta_t}^R = 1$ is as follow. If there is an increment (decrement) in infection rate of TB β_t by 10%, then there will be an increment (decrement) of the basic reproduction number R_t by 10%. For $\gamma_{\delta}^R = -1.5$, if there is an increment (decrement) in natural death rate δ by 10%, then there will be a decrement (increment) of basic reproduction ratio R_t by 15%.

4. Analysis of optimal control

In this section, we analyzed model (1) with its control functions u_1 and u_2 and the cost function (2). We used the Pontryagin Maximum Principle to obtain the optimal controls u_1^* and u_2^* such that condition (3) with constraint model (1) holds[14]. The Pontryagin Maximum Principle converts equations (1–3) into a minimizing Hamiltonian function problem with respect (u_1, u_2) . The Hamiltonian function H is as follow.

$$H(S, I, H_s, H_r, H_{st}, H_{rt}, A, u_1, u_2, \lambda_1, \lambda_2, \dots, \lambda_7) = I + H_{st} + H_{rt} + A + \frac{c_1}{2} u_1^2 + \frac{c_2}{2} u_2^2 + \sum_{i=1}^7 \lambda_i g_i$$

where g_i denotes the right hand side of model (1) which is the i -th state variable equation. The variables $\lambda_i, i=1,2,\dots,7$, are called adjoint variables satisfying the following co-state equations

$$\begin{aligned} \frac{d\lambda_1}{dt} &= (\lambda_1 - \lambda_2) \beta_t I + (\lambda_1 - \lambda_3) \beta_{hs} H_s + (\lambda_1 - \lambda_4) \beta_{hr} H_r + \lambda_1 \delta, \\ \frac{d\lambda_2}{dt} &= -1 + (\lambda_1 - \lambda_2) \beta_t S + (\lambda_2 - \lambda_1) u_1 \alpha_t + (\lambda_3 - \lambda_5) \bar{C}_s \beta_t H_s + (\lambda_4 - \lambda_6) \bar{C}_r \beta_t H_r + \lambda_2 (\delta + u_1), \\ \frac{d\lambda_3}{dt} &= (\lambda_1 - \lambda_3) \beta_{hs} S + (\lambda_3 - \lambda_5) \bar{C}_s \beta_t I + (\lambda_3 - \lambda_7) (1 - u_2) \gamma_1 + \lambda_3 \delta, \\ \frac{d\lambda_4}{dt} &= (\lambda_1 - \lambda_4) \beta_{hr} S + (\lambda_4 - \lambda_6) \bar{C}_r \beta_t I + (\lambda_4 - \lambda_7) (1 - u_2) \gamma_2 + \lambda_4 \delta, \\ \frac{d\lambda_5}{dt} &= -1 + (\lambda_5 - \lambda_3) u_1 \alpha_t + (\lambda_5 - \lambda_7) (1 - u_2) \gamma_3 + \lambda_5 (\delta + u_{st}), \\ \frac{d\lambda_6}{dt} &= -1 + (\lambda_6 - \lambda_4) u_1 \alpha_t + (\lambda_6 - \lambda_7) (1 - u_2) \gamma_4 + \lambda_6 (\delta + u_{rt}), \\ \frac{d\lambda_7}{dt} &= -1 + \lambda_7 (\delta + u_a) \end{aligned} \tag{6}$$

where the transversality conditions $\lambda_i(t_f) = 0, i = 1, \dots, 7$.

The procedure to obtain the optimal controls $u = (u_1^*, u_2^*)$ are as follows[15,16].

1. Minimize the Hamilton function H with respect to u , that is $\frac{\partial H}{\partial u} = 0$. The stationary condition gives

$$u_1^* = \begin{cases} 0 & \text{for } u_1 \leq 0 \\ \frac{(\lambda_6 - \lambda_4) \alpha_t H_{st} + (\lambda_2 - \lambda_1) \alpha_t I + (\lambda_5 - \lambda_3) \alpha_s H_{st}}{c_1} & \text{for } 0 < u_1 < 1 \\ 1 & \text{for } u_1 \geq 1 \end{cases}$$

$$u_2^* = \begin{cases} 0 & \text{for } u_2 \leq 0 \\ \frac{(\lambda_7 - \lambda_3) \gamma_1 H_s + (\lambda_7 - \lambda_4) \gamma_2 H_r + (\lambda_7 - \lambda_5) \gamma_3 H_{st} + (\lambda_7 - \lambda_6) \gamma_4 H_{rt}}{c_2} & \text{for } 0 < u_2 < 1 \\ 1 & \text{for } u_2 \geq 1 \end{cases}$$

2. Solve the state system $\dot{x}(t) = \frac{\partial H}{\partial \lambda}$ where $x = (S, I, H_s, H_r, H_{st}, H_{rt}, A)$, $\lambda = (\lambda_1, \lambda_2, \dots, \lambda_7)$ and the initial condition $x(0)$.

3. Solve the co-state system $\dot{\lambda}(t) = -\frac{\partial H}{\partial x}$ with the end condition

$$\lambda_i(t_f) = 0, i = 1, \dots, 7.$$

Applying the procedure, we obtained the optimal controls as follows.

Theorem 5. The optimal controls (u_1^*, u_2^*) that minimize the objective function $J(u_1, u_2)$ on Γ is given by

$$u_1^* = \max \left\{ 0, \min \left(1, \frac{(\lambda_6 - \lambda_4) \alpha_t H_{st} + (\lambda_2 - \lambda_1) \alpha_t I + (\lambda_5 - \lambda_3) \alpha_s H_{st}}{c_1} \right) \right\}$$

$$u_2^* = \max \left\{ 0, \min \left(1, \frac{(\lambda_7 - \lambda_3) \gamma_1 H_s + (\lambda_7 - \lambda_4) \gamma_2 H_r + (\lambda_7 - \lambda_5) \gamma_3 H_{st} + (\lambda_7 - \lambda_6) \gamma_4 H_{rt}}{c_2} \right) \right\}$$

where $\lambda_i, i = 1, \dots, 7$ is the solution of the co-state equation (6) with the transversality conditions $\lambda_i(t_f) = 0, i = 1, \dots, 7$.

The optimal system is obtained by substituting the optimal control (u_1^*, u_2^*) . The solutions of the optimality system will be solved numerically for some parameter choices. Most of the parameter values are assumed within realistic ranges due to lack of data.

5. Numerical simulation

In this section, we investigated the dynamic of model (1) with and without the optimal controls. We used iteration of 4-order Runge-Kutta method to obtain the optimal controls[17]. First, we solved the state equations using the forward 4-order Runge-Kutta method. Then we solved the co-state equations with the terminal conditions using the backward 4-order Runge-Kutta method. After that, we updated the controls using a convex combination of the previous controls and the value from the characterizations of u_1^* and u_2^* . This procedure was iterated. The iteration was stopped if the values of unknowns at the previous iteration are very close to the ones at the current iteration.

We considered three scenarios to explore the dynamics of TB-HIV co-infection. We considered the anti-TB treatment control u_1 in the

first scenario. In the second one, we considered the ARV treatment control u_2 . In the third scenario, we used the optimal anti-TB and ARV treatment controls u_1 and u_2 .

For these numerical simulations, we used parameters' values as in Table 2. Moreover, we used initial condition $[S(0), I(0), H_s(0), H_r(0), H_{sr}(0), H_{rt}(0), A(0)] = (5000, 100, 50, 30, 10, 10, 10)$, and weighting constants $c_1 = 80, c_2 = 100$.

5.1. First scenario

We deployed the anti-TB treatment control u_1 and set the ARV control u_2 to zero. The profile of the optimal control u_1^* is depicted in Figure 2. To reduce HIV resistance and TB co-infection in 10 years, the anti-TB treatment should be given intensively in the first nine years before decreasing to the lower bound in the end of the 10th year.





Figure 2. The profile of the optimal anti-TB control u_1^* .

From Figure 3A, we observed that the TB-infected subpopulation I decreased to zero by deploying the optimal control u_1^* and it increased without deploying u_1^* . Contrary, the result in Figure 3B shows that the AIDS subpopulation A tends to increase by deploying



the optimal control u_1^* compared with the case without control because there is no intervention against AIDS. For the sensitive-HIV-TB co-infection subpopulation H_{sr} , a decrease in the number of infected hosts is observed in Figure 4A in the presence of the optimal control u_1^* compared to an increase in the number of infected hosts in the absence of the control u_1^* . Similarly, in Figure 4B, this control strategy results in a significant decrease in the number of resistant-HIV and TB co-infection subpopulation H_{rt} as against an increase in the uncontrolled case. Hence, the anti-TB treatment control u_1^* gives a significant effect in controlling the TB-infected, sensitive-HIV and TB co-infection subpopulations.

5.2. Second scenario

Here, we deployed the ARV treatment control u_2 and set the anti-TB treatment control u_1 to zero. The optimal control profile of ARV treatment u_2^* is shown in Figure 5. We can see that to eliminate resistant-HIV and TB co-infection in 10 years, the ARV treatment should be given intensively during the first year before it drops gradually and vanishes at the end of second year.

With this strategy, we observed in Figures 6 and 7 that there is not a significant difference in the number of TB infection, AIDS infection, HIV-TB co-infection with and without the ARV control treatment only. The result in Figures 6 and 7 clearly suggests that this strategy is not very effective in the control of the number of the infected cases.

5.3. Third scenario

In the third scenario, the anti-TB and ARV treatment controls u_1 and u_2 are used simultaneously. The profile of the optimal anti-TB treatment control u_1^* and ARV control u_2^* of this scenario is given in Figure 8. To reduce resistant-HIV and TB co-infection in 10 years, the anti-TB and ARV treatment should be given intensively during the first nine years




Figure 3. The dynamics of I (A) and A (B) using the optimal control u_1^* .




Figure 4. The dynamics of H_{st} (A) and H_r (B) using the optimal control u_1^* .

and it drops gradually and vanishes at the end of the 10th year.




Figure 5. The profile of the optimal ARV control u_2^* .

Using the optimal controls in Figure 8, the dynamics of the TB, AIDS, HIV-TB co-infection subpopulations are given in Figures 9 and 10. For this strategy, we observed in Figure 9 that the control strategies resulted in a decrease in the number of TB infected and AIDS infected subpopulations compared to the number without control. A similar decrease is observed in Figure 10 for HIV-TB co-infection with drug-sensitivity and drug-resistance to ARV in the control strategy, while an increased number for the uncontrolled case was observed.

Our numerical results suggest that the combination of anti-TB treatment and ARV treatment is the most effective to eliminate the number of TB infection, AIDS infection and HIV-TB co-infection with drug-sensitivity and drug-resistance. Thus, if we can employ one treatment only, then anti-TB treatment is better than ARV treatment to reduce the number of TB infected and two strains HIV-TB co-infected populations.




Figure 6. The dynamics of I (A) and A (B) using the optimal control u_2^* .




Figure 7. The dynamics of H_s (A) and H_r (B) using the optimal control u_2^* .




Figure 8. The profile of the optimal controls u_1^* and u_2^* .

6. Conclusion

In this paper, we have developed a deterministic mathematical model for the spread of two strains HIV and TB co-infection that incorporates anti-TB and ARV treatment as optimal control strategies. For the model without controls, we obtained three thresholds R_p , R_s and R_r which are the basic reproduction ratios for the TB and two strains of HIV infections respectively. These ratios determine the existence and stability of the equilibria of the model. If the thresholds are less than unity, the diseases-free equilibrium is locally asymptotically stable. Finally, the conditions for existence of optimal control were studied analytically using the Pontryagin Maximum Principle. Our numerical simulation of the optimal control indicates that the best strategy is to combine the anti-TB and ARV treatments in order to reduce the two strains HIV and TB co-infection. However, if we have to use only one control, the anti-TB




Figure 9. The dynamics of I (A) and A (B) using the optimal controls u_1^* and u_2^* .




Figure 10. The dynamics of H_{st} (A) and H_{rt} (B) using the optimal controls u_1^* and u_2^* .

treatment is more effective than ARV treatment to eliminate the number of two strains HIV and TB co-infected subpopulations.

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgements

Parts of this research is funded by the Indonesian Directorate General for Higher Education (DIKTI) through DIPA DITLITABMAS Universitas Airlangga 2015 according to SK Rektor (No.: 516/UN3/2015).

References

[1] World Health Organization. HIV/AIDS. Geneva: World Health Organization; 2016. [Online] Available from: <http://www.who.int/mediacentre/factsheets/fs360/en/> [Accessed on 29th November, 2016]

[2] World Health Organization. HIV drug resistance. Geneva: World Health Organization; 2016. [Online] Available from: <http://www.who.int/hiv/topics/drugresistance/en/> [Accessed on 29th November, 2016]

[3] World Health Organization. Tuberculosis. Geneva: World Health Organization; 2017. [Online] Available from: <http://www.who.int/mediacentre/factsheets/fs104/en/> [Accessed on 7th June, 2017]

[4] Mallela A, Lenhart S, Vaidya NK. HIV-TB co-infection treatment: modeling and optimal control theory perspectives. *J Comput Appl Math* 2016; **307**: 143-61.

[5] Naresh R, Sharma D, Tripathi A. Modelling the effect of tuberculosis on the spread of HIV infection in a population with density-dependent birth and death rate. *Math Comput Model* 2009; **50**: 1154-66.

[6] Sharomi O, Podder CN, Gumel AB. Mathematical analysis of the transmission dynamics of HIV/TB co-infection in the presence of treatment. *Math Biosci Eng* 2008; **5**(1): 145-74.

[7] Augusto FB, Adekunle AI. Optimal control of a two-strain tuberculosis-HIV/AIDS model. *Biosystems* 2014; **119**: 20-44.

[8] Fatmawati, Tasman H. An optimal treatment control of TB-HIV coinfection. *Int J Math Math Sci* 2016; **2016**: 8261208.

[9] Makinde OD, Okosun KO. Impact of chemo-therapy on optimal control of malaria disease with infected immigrants. *Biosystems* 2011; **104**: 32-41.

[10] Okosun KO, Makinde OD, Takaidza I. Impact of optimal control on the treatment of HIV/AIDS and screening of unaware infectives. *Appl Math Model* 2013; **37**: 3802-20.

[11] Diekmann O, Heesterbeek JAP, Metz JAJ. On the definition and the computation of the basic reproduction ratio R_0 in models for infectious diseases in heterogenous populations. *J Math Biol* 1990; **28**: 362-82.

[12] Diekmann O, Heesterbeek JAP. *Mathematical epidemiology of infectious diseases, model building, analysis and interpretation*. New York: John Wiley & Son; 2000.

[13] Chitnis N, Hyman JM, Cushing JM, Determining important parameters in the spread of malaria through the sensitivity analysis of a mathematical model. *Bull Math Biol* 2008; **70**: 1272-96.

[14] Pontryagin LS, Boltyanskii VG, Gamkrelidze VG, Mishchenko EF. *The mathematical theory of optimal processes*. New York: John Wiley & Sons; 1962.

[15] Lewis FL, Syrmos VL. *Optimal control*. 2nd ed. New York: John Wiley & Sons; 1995.

[16] Naidu DS. *Optimal control systems*. Boca Raton: CRC Press; 2002.

[17] Lenhart S, Workman JT. *Optimal control applied to biological models*. London: Chapman and Hall; 2007.